InSite Vision focuses on developing new specialty ophthalmic products, including three late stage programs.
Sun Pharma is in the process of establishing a branded ophthalmic business in the US and these deals will give access to four late stage branded ophthalmic products in the US.
For the 6-month period ended June 30, 2015, InSite Vision recorded revenues of USD 3.8 million, an EBITDA loss of USD 6.4 million and a net loss of USD 7.5 million.
The share has been in limelight post the company's subsidiary Taro launching Keveyis which is used to treat periodic paralysis.
For More Information :Intraday Trading Tips, Intraday Stock Tips,F&O tips,Stock Future Tips, Intraday Tips ,Option Trading Tips,Stock Option Tips,Future & Option Tips,option tips